LB Pharmaceuticals (NASDAQ:LBRX) Releases Quarterly Earnings Results, Meets Estimates

Key Points

• LB Pharmaceuticals reported quarterly EPS of ($0.45), which met analysts' consensus estimates.
• Several institutional investors including Deep Track Capital, RA Capital, TCG Crossover, Balyasny and Vivo purchased new stakes worth tens of millions, indicating strong institutional interest.
• Analyst sentiment is mixed but tilted positive with a MarketBeat average rating of Moderate Buy and a consensus price target of $33.33; Stifel raised its target to $35 while Weiss Ratings maintained a sell.

LB Pharmaceuticals (NASDAQ:LBRX - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.45) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.45), Zacks reports.

LB Pharmaceuticals Trading Down 0.2%

LBRX stock opened at $24.16 on Friday. The company's 50 day moving average is $23.51. The company has a market cap of $611.22 million and a price-to-earnings ratio of -39.61. LB Pharmaceuticals has a twelve month low of $13.36 and a twelve month high of $27.55.

Hedge Funds Weigh In On LB Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the stock. Deep Track Capital LP purchased a new position in shares of LB Pharmaceuticals in the 3rd quarter worth about $52,941,000. RA Capital Management L.P. bought a new stake in LB Pharmaceuticals during the 3rd quarter valued at about $28,058,000. TCG Crossover Management LLC bought a new stake in LB Pharmaceuticals during the 3rd quarter valued at about $27,554,000. Balyasny Asset Management L.P. purchased a new position in LB Pharmaceuticals in the third quarter worth about $15,289,000. Finally, Vivo Capital LLC bought a new position in shares of LB Pharmaceuticals in the third quarter worth approximately $12,632,000.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. Weiss Ratings reissued a "sell (e)" rating on shares of LB Pharmaceuticals in a research report on Monday, December 29th. Stifel Nicolaus lifted their price target on LB Pharmaceuticals from $27.00 to $35.00 and gave the company a "buy" rating in a research report on Thursday, December 11th. Finally, Roth Mkm started coverage on LB Pharmaceuticals in a research note on Friday, January 9th. They issued a "buy" rating and a $31.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $33.33.

LB Pharmaceuticals Company Profile

We are a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. We are building a pipeline that leverages the broad therapeutic potential of our lead product candidate, LB-102, which we believe has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries, not including the United States, because the development and regulatory requirements of the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.